# A Non-Interventional Study of Clinical Characteristics and Mortality of US Patients With Fibrodysplasia Ossificans Progressiva (FOP)

> **NCT06064656** · — · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 131 (actual)

## Conditions studied

- Fibrodysplasia Ossificans Progressiva (FOP)

## Interventions

- **OTHER:** Non-Interventional

## Key facts

- **NCT ID:** NCT06064656
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-29
- **Primary completion:** 2023-09-22
- **Final completion:** 2023-09-29
- **Target enrollment:** 131 (ACTUAL)
- **Last updated:** 2025-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06064656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06064656, "A Non-Interventional Study of Clinical Characteristics and Mortality of US Patients With Fibrodysplasia Ossificans Progressiva (FOP)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06064656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*